GALECTIN THERAPEUTICS INC 8-K

What Happened

• Galectin Therapeutics Inc. filed a Form 8-K on March 31, 2026 to announce its results of operations and financial condition as of and for the year ended December 31, 2025, and to provide a business update. The company’s press release dated March 31, 2026 is incorporated by reference in the filing.

Key Details

• Filing date: March 31, 2026; reporting period: year ended December 31, 2025.
• The press release containing the results and update is attached to the 8-K (Exhibit 99.1).
• The company’s statements include forward‑looking language and rely on the safe harbor under the Private Securities Litigation Reform Act of 1995.
• Investors are directed to the “Risk Factors” in Galectin’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for additional risk disclosures.

Why It Matters

• This 8-K is the company’s official disclosure of its full-year 2025 financial results and a management business update—information investors use to assess performance and outlook.
• Because the filing contains forward‑looking statements, investors should review the press release and the referenced 10-K risk factors to understand assumptions and potential risks before making investment decisions.